Treatment · Experimental
Anticoagulation / antiplatelet therapy
One of the most debated long COVID treatments: thinning the blood to clear microclots">microclots">microclots. The hypothesis is compelling to many patients, but the evidence is thin and observational, and the bleeding risk is real.
Short version: blood-thinning to target microclots rests on small, uncontrolled reports while large anticoagulation trials in COVID were neutral. The microclot test is unvalidated and bleeding risk is serious. Honest hypothesis, not a proven treatment.
The idea
If fibrinaloid microclots and sticky platelets block small-vessel flow, then thinning the blood and quietening platelets might restore it. Some clinicians have used a triple regimen (two antiplatelets plus an anticoagulant).1
What the evidence really is
The supporting reports are small, observational, and not placebo-controlled, mostly from a single group. Meanwhile large anticoagulation trials in acute COVID were largely neutral, and the microclot test itself is not yet validated by independent labs.1
contested bleeding risk
Why caution matters
Triple therapy carries a real risk of serious bleeding, and even its proponents stress strict medical supervision. This page describes the hypothesis honestly; it is not an endorsement, and self-treating with blood thinners is dangerous.
What we don't know
Honest about the edges of the evidence. These are open questions, not settled answers.
- Whether any controlled trial shows benefit.
- How to weigh bleeding risk against uncertain benefit.
- Whether the microclot test replicates across labs.
- Which patients, if any, are appropriate.
References
Every reference is free to read in full.